Ligand's 15min chart shows KDJ Golden Cross, Bullish Marubozu.

Ligand's 15-minute chart recently exhibited a significant bullish technical indicator, as it triggered a KDJ Golden Cross and a Bullish Marubozu at 13:30 on July 7, 2025. This suggests a notable shift in momentum, with the stock price potentially continuing its upward trajectory. The strong presence of buyers in the market indicates a high likelihood of continued bullish momentum, underscoring the market's control by buyers.

Ligand Pharmaceuticals (LGND) has recently exhibited a notable bullish technical indicator, with its 15-minute chart triggering a KDJ Golden Cross and a Bullish Marubozu at 13:30 on July 7, 2025. This significant shift in momentum suggests a potential continuation of the stock's upward trajectory. The strong presence of buyers in the market indicates a high likelihood of sustained bullish momentum, underscoring the market's control by buyers.

This positive technical signal comes amidst significant developments for Ligand, including the formation of Pelthos Therapeutics through a merger with Channel Therapeutics. Pelthos, which will begin trading under the ticker "PTHS" on NYSE American on July 2, 2025, secured $50.1 million in equity funding. Ligand itself invested $18 million and is set to receive a 13% royalty on the global sales of ZELSUVMI™, the first FDA-approved home-administered treatment for Molluscum contagiosum [1].

ZELSUVMI™ targets a market of 16.7 million potential patients in the US and is notable for being the first prescription medication that can be administered at home. The launch of ZELSUVMI is anticipated in July 2025, marking a significant move for Pelthos into the biopharmaceutical market.

Beyond the launch of ZELSUVMI, Pelthos plans to evaluate Channel's NaV 1.7 programs, which target various pain treatments, potentially expanding the company's avenue for future therapeutic solutions.

The bullish technical indicators and the strategic merger underscore the positive outlook for Ligand Pharmaceuticals, suggesting a strong potential for continued growth and investor interest.

References:
[1] https://www.gurufocus.com/news/2957060/ligand-announces-completion-of-pelthos-therapeutics-merger-with-channel-therapeutics-lgnd-stock-news